European Union - English - EMA (European Medicines Agency)

zentiva k.s. - efavirenz, emtricitabine, tenofovir disoproxil, phosphate - hiv infections - antivirals for systemic use, - efavirenz/emtricitabine/tenofovir disoproxil zentiva is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. it is indicated for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adults aged 18 years and over with virologic suppression to hiv-1 rna levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in efavirenz/emtricitabine/tenofovir disoproxil zentiva prior to initiation of their first antiretroviral treatment regimen., the demonstration of the benefit of the combination efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavir

European Union - English - EMA (European Medicines Agency)

bayer ag - riociguat - hypertension, pulmonary - antihypertensives for pulmonary arterial hypertension - chronic thromboembolic pulmonary hypertension (cteph) adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah) adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. efficacy has been shown in a pah population including aetiologies of idiopathic or heritable pah or pah associated with connective tissue disease.

European Union - English - EMA (European Medicines Agency)

allergan pharmaceuticals ireland - bimatoprost, timolol - glaucoma, open-angle, ocular hypertension - ophthalmologicals, - reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

Malta - English - Medicines Authority

fresenius medical care deutschland gmbh d-61346 bad homburg, germany - calcium, glucose - solution for peritoneal dialysis - calcium 1.25 mmol/l glucose 1.5 % (w/v) - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

fresenius medical care deutschland gmbh d-61346 bad homburg, germany - calcium, glucose - solution for peritoneal dialysis - calcium 1.25 mmol/l glucose 2.3 % (w/v) - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

fresenius medical care deutschland gmbh d-61346 bad homburg, germany - calcium, glucose - solution for peritoneal dialysis - calcium 1.25 mmol/l glucose 4.25 % (w/v) - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

fresenius medical care deutschland gmbh d-61346 bad homburg, germany - calcium, glucose - solution for peritoneal dialysis - calcium 1.75 mmol/l glucose 1.5 % (w/v) - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

fresenius medical care deutschland gmbh d-61346 bad homburg, germany - calcium, glucose - solution for peritoneal dialysis - calcium 1.75 mmol/l glucose 2.3 % (w/v) - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

fresenius medical care deutschland gmbh d-61346 bad homburg, germany - calcium, glucose - solution for peritoneal dialysis - calcium 1.75 mmol/l glucose 4.25 % (w/v) - blood substitutes and perfusion solutions